CASE SERIES

Cutaneous manifestations of COVID-19: report of three cases

Imen Chaabane1,2 · Manel Loukil1,3 · Raja Amri1,2 · Imen Badri1,3 · Hajer Baha1,2 · Manel Lajmi1,2 · Khaled Bouzaidi1,4 · Hedia Ghairri1,3

Received: 24 May 2020 / Revised: 1 July 2020 / Accepted: 31 July 2020 / Published online: 7 September 2020
© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Abstract
Coronavirus disease 2019 (COVID-19) shows rapid spread around the world. Its classic presentation is a respiratory illness. However, cutaneous manifestations have rarely been described as the first clinical manifestation in patients with this infection. The aim of this article is to describe cutaneous manifestations in patients with COVID-19 through three case reports.

Keywords COVID-19 · Cutaneous manifestations · COVID-19 symptoms

Introduction
Coronavirus disease 2019 (COVID-19), first detected in Wuhan City on December 31, 2019, has emerged as a public health emergency [1]. In Tunisia, the epidemic phase of COVID-19 began in March 2020 and resulted in implementing special emergency measures. By May 2, 2020, 1013 confirmed cases and 42 deaths have been caused by COVID-19.

The most common symptoms of COVID-19 are fever, dry cough, fatigue, myalgia and dyspnea [1–3]. However, other symptoms have been reported, including gastrointestinal and neurological manifestations. Cutaneous lesions were not recognized at the early stages of the pandemic, but have received much recent attention in scientific journals [4–8].

This article describes three cases of COVID-19 revealed by cutaneous manifestations.

Case 1
A 20-year-old woman, belonging to medical staff, presented cervical, axillary and inguinal nodes. Four days later, she developed a fever and pruritic maculopapular lesions (Fig. 1) and urticaria (Fig. 2) on the trunk. Subsequently, the rashes spread to form target lesions (erythema multiform like), painful eroded and ulcerated papules, small plaques on the upper limbs (Fig. 3a, b) and purple to blue lesions in the thighs (Fig. 4). Laboratory tests revealed a lymphopenia. The naso-pharyngeal swab tested for SARS-CoV-2 RNA amplification was positive. In the following days, she developed dry cough. The oxygen saturation was 98%. The chest CT scan was normal. She remained hemodynamically stable, and she had not any treatment. The patient cured from COVID-19 about one month after the start of the clinical picture; she kept post-inflammatory hyperpigmentation on the thighs (Fig. 5).

Case 2
A 35-year-old woman, belonging to medical staff, presented burning retrosternal discomfort and a dry cough without fever 7 days after a contact with COVID-19 patient. Three days later, she developed itchy rash on upper chest (Fig. 6) and livedo reticularis on the arm (Fig. 7). The naso-pharyngeal swab tested for SARS-CoV-2 RNA amplification was positive. Evolution was favorable in 14 days, and the cutaneous manifestations were completely disappearing after 3 days.
Case 3

A 36-year-old woman complained of arthralgia, myalgia and low-grade fever. She was living with her husband, who was diagnosed with COVID-19. The naso-pharyngeal swab tested for SARS-CoV-2 RNA amplification was positive. Four days later, she developed a maculopapular rash on sub-mammary fold and trunk, anosmia and ageusia. These cutaneous lesions healed in 7 days.

Discussion

Coronavirus disease 2019 (COVID-19) is an emerging infectious disease. Increasing evidence shows that coronavirus isn’t always confined to the respiratory tract. However, skin manifestations are increasingly reported in the literature.

Cutaneous manifestations present less than 1% of the cases in the Chinese epidemiological series [1] and more than 20% of the cases (18 confirmed cases out of 88) in Italian series in Lombardy [9]. However, their exact incidence is unknown due to the fact that these lesions were often missed in the epidemiological studies since COVID-19 testing was not done for most of mild disease cases and lesions may be transitory.

Most of these publications lack iconography because of the high risk of contagion. The most common manifestations reported were maculopapular rash and generalized urticaria [9–11]. However, chickenpox-like lesions, livedo, cutaneous necrosis, erythema multiform and pseudo-chilblain lesions were rarely reported [4–6, 12]. The majority of these lesions were localized on the trunk, and they occurred at the onset of the disease like in our cases [8, 9]. The majority of
studies have reported no correlation between the severity of COVID-19 and skin involvement [8].

Almost all studies reported the healing of the cutaneous lesions between 7 and 10 days [9]. In our study, one patient is keeping a scar.

In our case reports, the same patient had several aspects of skin involvement. In general, it is very uncommon that

---

**Fig. 4** Purple to blue lesions in the thighs

**Fig. 5** Postinflammatory hyperpigmentation on the thighs

**Fig. 6** Itchy rash on upper chest

**Fig. 7** Livedo reticularis on the arm
a virus can lead to various cutaneous manifestations, and especially in the same patient. The mechanisms of this polymorphism remain poorly elucidated.

It was underlined that the COVID-19 infection can lead to systemic vasculitis manifestations and thrombotic disease, thus causing several complications [13–16]. The clinical manifestations may depend on the location, the size and the depth of the vessels involved [17]. The pathophysiological mechanisms of dermatological manifestations of COVID-19 are not well documented. The lymphocytic vasculitis and microthrombi described in some studies may be induced by blood immune complexes that activate cytokines [16, 18, 19]. The virus could also induce a modification in the structure of the keratinocyte [19].

In conclusion, paucisymptomatic patients who initially presented with skin involvement are easily missed or misdiagnosed as other viral or allergic diseases. So, the clinician should be aware of this skin involvement in COVID-19 to make early diagnosis. On another side, further histological and clinical studies are required to better illustrate the cutaneous features and the vasculitis mechanisms.

Acknowledgements None.

Authors’ contributions ICH and IB conceived the study, participated in its design, and coordinated and helped to draft the manuscript. MLJ and HB conceived the study and participated in its design. RA and ML helped to draft the manuscript. HGH and KB read and approved the final manuscript.

Funding None

Compliance with ethical standards

Conflicts of interest The authors declare that they have no conflicts of interest concerning this article.

References

1. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382(18):1708–1720
2. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z (2020) Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med 35(5):1545–1549
3. Yu X, Sun X, Cui P, Pan H, Lin S, Han R et al (2020) Epidemiological and clinical characteristics of 333 confirmed cases with coronavirus disease 2019 in Shanghai, China. Transbound Emerg Dis. 1:1. https://doi.org/10.1111/tbed.13604
4. Manalo IF, Smith MK, Cheeley J, Jacobs R (2020) A dermatologic manifestation of COVID-19: transient livedo reticularis. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2020.04.018
5. Galván Casas C, Catalá A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández Nieto D, Rodríguez-Villa Lario A et al (2020) Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 10:29. https://doi.org/10.1111/BJD.19163
6. Torres-Navarro I, Abril-Pérez C, Roca-Ginés J, Sánchez-Arráz P, Botella-Estrada R, Évole-Buselli M (2020) Comment on “Two cases of COVID-19 presenting with a clinical picture resembling chilblains: first report from the Middle East”: pernio unrelated to COVID-19. Clin Exp Dermatol. https://doi.org/10.1111/CED.14255
7. Estébanez A, Pérez-Santiago L, Silva E, Guillen-Climent S, Garcia-Vázquez A, Ramón MD (2020) Cutaneous manifestations in COVID-19: a new contribution. J Eur Acad Dermatol Venereol 1:1. https://doi.org/10.1111/jdv.16474
8. Sachdeva M, Gianotti R, Shah M, Lucia B, Tosi D, Veraldi S et al (2020) Cutaneous manifestations of COVID-19: report of three cases and a review of literature. J Dermatol Sci. https://doi.org/10.1016/j.jdermsci.2020.04.011
9. Recalcati S (2020) Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 1:1. https://doi.org/10.1111/jdv.16387
10. Tammaro A, Abebanjo G, Parisella FR, Pezzuto A, Rello J (2020) Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome. J Eur Acad Dermatol Venereol. https://doi.org/10.1111/jdv.16530
11. Medeiros VLS, Silva LFT (2020) Follow-up of skin lesions during the evolution of COVID-19: a case report. Arch Dermatol Res. https://doi.org/10.1007/s00403-020-02091-0
12. Marzano AV, Genovese G, Fabbrocini G, Pigatto P, Monfrecola G, Piraccini BM et al (2020) Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2020.04.044
13. Bökdeli B, Madhavan MV, Jiménez D, Chuich T, Dreyfus I, Driggin E et al (2020) COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2020.04.031
14. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q et al (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2020.1127
15. Pleasure SJ, Green AJ, Josephson SA (2020) The spectrum of neurologic disease in the severe acute respiratory syndrome coronavirus 2 pandemic infection: neurologists move to the frontlines. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2020.1065
16. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harj J et al (2020) Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. https://doi.org/10.1016/j.trsl.2020.04.007
17. Frumholtz L, Laurent-Roussel S, Lipsker D, Terrier B (2020) Cutaneous vasculitis: review on diagnosis and clinicopathologic correlations. Clin Exp Allergy Immunol. https://doi.org/10.1007/s12016-020-08788-4
18. Cordero KM, Reynolds SD, Wattier R, McCalmon TH (2020) Clustered cases of acral perniosis: clinical features, histopathology and relationship to COVID-19. Pediatr Dermatol. https://doi.org/10.1111/pde.14227
19. Gianotti R, Zerbi P, Dodiuk-Gad RP (2020) Clinical and His- topathological study of skin dermatoses in patients affected by COVID-19 infection in the Northern part of Italy. J Dermatol Sci. https://doi.org/10.1016/j.jdermsci.2020.04.007

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.